

OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Francesco Squadrito,
francesco.squadrito@unime.it

SPECIALTY SECTION

This article was submitted to Integrative and Regenerative Pharmacology, a section of the journal Frontiers in Pharmacology

RECEIVED 18 October 2022 ACCEPTED 19 October 2022 PUBLISHED 21 November 2022

CITATION

Squadrito F, Bitto A, Irrera N, Pizzino G, Pallio G, Minutoli L and Altavilla D (2022), Corrigendum: Pharmacological activity and clinical use of PDRN. Front. Pharmacol. 13:1073510. doi: 10.3389/fphar.2022.1073510

COPYRIGHT

© 2022 Squadrito, Bitto, Irrera, Pizzino, Pallio, Minutoli and Altavilla. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: Pharmacological activity and clinical use of PDRN

Francesco Squadrito¹*, Alessandra Bitto¹, Natasha Irrera¹, Gabriele Pizzino¹, Giovanni Pallio¹, Letteria Minutoli¹ and Domenica Altavilla²

¹Section of Pharmacology, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy, ²Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy

KEYWORDS

adenosine A2 receptors, DNA, oligonucleotides, PDRN, wound healing

A Corrigendum on

Pharmacological activity and clinical use of PDRN

by Squadrito F, Bitto A, Irrera N, Pizzino G, Pallio G, Minutoli L and Altavilla D (2017). Front. Pharmacol. 8:224. doi: 10.3389/fphar.2017.00224

In the published article, the **Conflict of Interest** statement was incorrectly filed. Disclaimers on patents were omitted from the article. The correct Conflict of Interest statement appears below.

"Author FS has received research support from Mastelli for work on polydeoxyribonucleotide. Authors FS, AB, and DA are co-inventors on a patent describing therapeutic polydeoxyribonucleotide activity in chronic intestinal disease. Author LM is a co-inventor on a patent describing therapeutic polydeoxyribonucleotide activity in testicular injury by torsion.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.